{
  "name": "Hormone_Diagnosis",
  "remarks": [
    "This module checks for HER2 and then assigns either HER2 positive/negative. This follows suit for ER and PR. Finally, it accounts for the Triple negative factor at the end. "
  ],
  "states": {
    "Initial": {
      "type": "Initial",
      "direct_transition": "Human_Epidermal_Growth_Factor_Receptor_2__HER2__Detection___Fluorescence_in_situ_Hybridization__FISH_"
    },
    "Terminal": {
      "type": "Terminal"
    },
    "Human_Epidermal_Growth_Factor_Receptor_2__HER2__Detection___Fluorescence_in_situ_Hybridization__FISH_": {
      "type": "Procedure",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": "434363004",
          "display": "Human epidermal growth factor receptor 2 gene detection by fluorescence in situ hybridization (procedure)"
        }
      ],
      "duration": {
        "low": 1,
        "high": 2,
        "unit": "days"
      },
      "remarks": [
        "Fluorescence in situ hybridization (FISH), which detects the number of HER2 genes in the cancer cells:",
        "https://ww5.komen.org/BreastCancer/TumorCharacteristics.html",
        "",
        "FISH results are usually available from the lab within a few days:",
        "https://www.verywellhealth.com/fish-test-2252457"
      ],
      "direct_transition": "Human_Epidermal_Growth_Factor_Receptor_2_HER2_Detection_Immunochemistry",
      "reason": "breast_cancer_condition"
    },
    "HER2_negative": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "85319-2",
          "display": "HER2 [Presence] in Breast cancer specimen by Immune stain"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": "260385009",
        "display": "Negative (qualifier value)"
      },
      "direct_transition": "HER2 ratio less than 1point8"
    },
    "HER2_positive": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "85319-2",
          "display": "HER2 [Presence] in Breast cancer specimen by Immune stain"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": "10828004",
        "display": "Positive (qualifier value)"
      },
      "direct_transition": "HER2_ratio_greater_than_2point2"
    },
    "Tumor_Biopsy_to_Test_Estrogen_Receptor_Status": {
      "type": "Simple",
      "distributed_transition": [
        {
          "transition": "ER_negative",
          "distribution": 0.2
        },
        {
          "transition": "ER_positive",
          "distribution": 0.8
        }
      ],
      "remarks": [
        "About 80% of all breast cancers are “ER-positive.” That means the cancer cells grow in response to the hormone estrogen.:",
        "https://www.webmd.com/breast-cancer/breast-cancer-types-er-positive-her2-positive#1"
      ]
    },
    "ER_negative": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "85337-4",
          "display": "Estrogen receptor Ag [Presence] in Breast cancer specimen by Immune stain"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": "260385009",
        "display": "Negative (qualifier value)"
      },
      "direct_transition": "ER-"
    },
    "ER_positive": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "85337-4",
          "display": "Estrogen receptor Ag [Presence] in Breast cancer specimen by Immune stain"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": "10828004",
        "display": "Positive (qualifier value)"
      },
      "direct_transition": "ER+"
    },
    "Tumor_Biopsy_to_Test_Progesterone_Receptor_Status": {
      "type": "Simple",
      "distributed_transition": [
        {
          "transition": "PR_negative",
          "distribution": 0.35
        },
        {
          "transition": "PR_positive",
          "distribution": 0.65
        }
      ],
      "remarks": [
        "About 80% of all breast cancers are “ER-positive.” That means the cancer cells grow in response to the hormone estrogen. About 65% of these are also “PR-positive.” They grow in response to another hormone, progesterone.:",
        "https://www.webmd.com/breast-cancer/breast-cancer-types-er-positive-her2-positive#1"
      ]
    },
    "PR_negative": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "85339-0",
          "display": "Progesterone receptor Ag [Presence] in Breast cancer specimen by Immune stain"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": "260385009",
        "display": "Negative (qualifier value)"
      },
      "direct_transition": "PR-"
    },
    "PR_positive": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "85339-0",
          "display": "Progesterone receptor Ag [Presence] in Breast cancer specimen by Immune stain"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": "10828004",
        "display": "Positive (qualifier value)"
      },
      "direct_transition": "PR+"
    },
    "Overall_Receptor_Analysis": {
      "type": "Simple",
      "remarks": [
        "If all hormones are negative transition to triple negative"
      ],
      "conditional_transition": [
        {
          "transition": "Hormone Receptor Negative",
          "condition": {
            "condition_type": "And",
            "conditions": [
              {
                "condition_type": "Attribute",
                "attribute": "breast_cancer_ER",
                "operator": "==",
                "value": "ER-negative"
              },
              {
                "condition_type": "Attribute",
                "attribute": "breast_cancer_PR",
                "operator": "==",
                "value": "PR-negative"
              }
            ]
          }
        },
        {
          "transition": "Hormone Receptor Positive",
          "condition": {
            "condition_type": "And",
            "conditions": [
              {
                "condition_type": "Attribute",
                "attribute": "breast_cancer_ER",
                "operator": "==",
                "value": "ER-positive"
              },
              {
                "condition_type": "Attribute",
                "attribute": "breast_cancer_PR",
                "operator": "==",
                "value": "PR-positive"
              }
            ]
          }
        },
        {
          "transition": "Terminal"
        }
      ]
    },
    "HER2-": {
      "type": "SetAttribute",
      "attribute": "breast_cancer_HER2",
      "direct_transition": "Tumor_Biopsy_to_Test_Estrogen_Receptor_Status",
      "value": "HER2-negative"
    },
    "HER2+": {
      "type": "SetAttribute",
      "attribute": "breast_cancer_HER2",
      "value": "HER2-positive",
      "direct_transition": "Tumor_Biopsy_to_Test_Estrogen_Receptor_Status"
    },
    "ER-": {
      "type": "SetAttribute",
      "attribute": "breast_cancer_ER",
      "direct_transition": "Tumor_Biopsy_to_Test_Progesterone_Receptor_Status",
      "value": "ER-negative"
    },
    "ER+": {
      "type": "SetAttribute",
      "attribute": "breast_cancer_ER",
      "direct_transition": "Tumor_Biopsy_to_Test_Progesterone_Receptor_Status",
      "value": "ER-positive"
    },
    "PR-": {
      "type": "SetAttribute",
      "attribute": "breast_cancer_PR",
      "direct_transition": "Overall_Receptor_Analysis",
      "value": "PR-negative"
    },
    "PR+": {
      "type": "SetAttribute",
      "attribute": "breast_cancer_PR",
      "direct_transition": "Overall_Receptor_Analysis",
      "value": "PR-positive"
    },
    "Triple_Negative": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "21924-6",
          "display": "Tumor marker Cancer"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": "260385009",
        "display": "Negative (qualifier value)"
      },
      "direct_transition": "Triple_Negative_Patient",
      "remarks": [
        "In women with triple-negative breast cancer, the malignant cells do not contain receptors for estrogen, progesterone or HER2. Breast cancer that is ER-, PR- and HER2-negative cannot be treated with hormone therapy or medications that work by blocking HER2, such as trastuzumab."
      ]
    },
    "Hormone Receptor Positive": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "10480-2",
          "display": "Estrogen+Progesterone receptor Ag [Presence] in Tissue by Immune stain"
        }
      ],
      "direct_transition": "Terminal",
      "value_code": {
        "system": "SNOMED-CT",
        "code": "10828004",
        "display": "Positive (qualifier value)"
      },
      "remarks": [
        "Hormone receptor-positive (estrogen receptor-positive (ER-positive)/progesterone receptor-positive (PR-positive)) tumors express (have a lot of) hormone receptors.:",
        "https://ww5.komen.org/BreastCancer/TumorCharacteristics.html"
      ]
    },
    "Hormone Receptor Negative": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "",
      "codes": [
        {
          "system": "LOINC",
          "code": "10480-2",
          "display": "Estrogen+Progesterone receptor Ag [Presence] in Tissue by Immune stain"
        }
      ],
      "value_code": {
        "system": "SNOMED-CT",
        "code": "260385009",
        "display": "Negative (qualifier value)"
      },
      "conditional_transition": [
        {
          "transition": "Triple_Negative",
          "condition": {
            "condition_type": "Attribute",
            "attribute": "breast_cancer_HER2",
            "operator": "==",
            "value": "HER2-negative"
          }
        },
        {
          "transition": "Terminal"
        }
      ],
      "remarks": [
        "Hormone receptor-negative (estrogen receptor-negative (ER-negative)/progesterone receptor-negative (PR- negative)) tumors do not express (have few or no) hormone receptors.:",
        "https://ww5.komen.org/BreastCancer/TumorCharacteristics.html"
      ]
    },
    "Human_Epidermal_Growth_Factor_Receptor_2_HER2_Detection_Immunochemistry": {
      "type": "Procedure",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": "433114000",
          "display": "Human epidermal growth factor receptor 2 gene detection by immunohistochemistry (procedure)"
        }
      ],
      "duration": {
        "low": 2,
        "high": 4,
        "unit": "hours"
      },
      "remarks": [
        "Immunohistochemistry (IHC), which detects the number of HER2 protein receptors in the cancer cells:",
        "https://ww5.komen.org/BreastCancer/TumorCharacteristics.html",
        "",
        "In about 20% of breast cancers, the cells make too much of a protein known as HER2. These cancers tend to be aggressive and fast-growing:",
        "https://www.webmd.com/breast-cancer/breast-cancer-types-er-positive-her2-positive#1",
        "",
        "All antibody-antigen interactions investigated in this study, both the primary antibody binding to its target and the secondary antibody binding to the primary, require several hours to reach equilibrium at the concentrations used:",
        "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878317/"
      ],
      "distributed_transition": [
        {
          "transition": "HER2_negative",
          "distribution": 0.8
        },
        {
          "transition": "HER2_positive",
          "distribution": 0.2
        }
      ],
      "reason": "breast_cancer_condition"
    },
    "Triple_Negative_Patient": {
      "type": "SetAttribute",
      "attribute": "breast_cancer_triple_negative",
      "direct_transition": "Terminal",
      "value": true
    },
    "HER2 ratio less than 1point8": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "ratio",
      "codes": [
        {
          "system": "LOINC",
          "code": "85318-4",
          "display": "HER2 [Presence] in Breast cancer specimen by FISH"
        }
      ],
      "direct_transition": "HER2-",
      "remarks": [
        "Title of the article: HER2 Evaluation and Its Impact on Breast Cancer Treatment Decisions",
        "",
        "https://wwwncbinlmnihgov/pmc/articles/PMC3225235/"
      ],
      "exact": {
        "quantity": "less than 1.8"
      }
    },
    "HER2_ratio_greater_than_2point2": {
      "type": "Observation",
      "category": "laboratory",
      "unit": "ratio",
      "codes": [
        {
          "system": "LOINC",
          "code": "85318-4",
          "display": "HER2 [Presence] in Breast cancer specimen by FISH"
        }
      ],
      "direct_transition": "HER2+",
      "remarks": [
        "Title of the article: HER2 Evaluation and Its Impact on Breast Cancer Treatment Decisions",
        "",
        "https://wwwncbinlmnihgov/pmc/articles/PMC3225235/"
      ],
      "exact": {
        "quantity": "greater than 2.2"
      }
    }
  },
  "gmf_version": 1
}